Bateman, Randall J.,Mawuenyega, Kwasi G.,Holtzman, David M.
申请号：
AU2017200029
公开号：
AU2017200029A1
申请日:
2017.01.04
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017200029A120170202.pdf#####ABSTRACT The invention is directed to an in vitro method for measuring the in vivo rate of amyloid beta (A3 ) turnover in the blood of a subject comprising: (a) determining by mass spectrometry the amount of labelled AP, or the amount of labelled A3 and unlabelled AP, in a blood sample obtained from the subject, (b) calculating the rate of AP clearance using the amount of labelled A, or the amount of labelled A3 and the amount of unlabelled A3, determined in step (a), wherein (i) the rate of AP clearance is calculated from the amount of labelled A, or the amount of labelled A3 and the amount of unlabelled A, in a sample obtained between 10 hours and 20 hours after intravenous administration by a 9 hour infusion has begun of at least one amino acid labelled with a stable nonradioactive isotope to the subject, or (ii) the rate of AP clearance is calculated from the amount of labelled AP, or the amount of labelled A3 and the amount of unlabelled AI, in a sample obtained after 4, 5, 6, 7, 8, 9, or 10 hours after oral or intravenous bolus administration of at least one amino acid labelled with a stable non-radioactive isotope to the subject.
